Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

K.B. Kim, R. Kefford, A.C. Pavlick, J.R. Infante, A. Ribas, J.A. Sosman, L.A. Fecher, Michael Millward, G.A. Mcarthur, P. Hwu, R. Gonzalez, P.A. Ott, G.V. Long, O.S. Gardner, D. Ouellet, Y. Xu, D.J. Demarini, N.T. Le, K. Patel, K.D. Lewis

    Research output: Contribution to journalArticlepeer-review

    371 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)482-489
    JournalJournal of Clinical Oncology
    Issue number4
    Publication statusPublished - 2013

    Cite this